Search
Scilex Holding Co
SCLXAdd to Watchlist
7.880USD
+0.080+1.03%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
66.91MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.03%
5 Days
+14.87%
1 Month
-1.38%
6 Months
-35.41%
Year to Date
-35.41%
1 Year
+30.46%
Key Figures
7.760Open
8.463High
43.75KVolume
LossP/E TTM
1.87P/E Dynamic
--Dividend TTM
0.62%Turnover Ratio
7.800Prev. Close
7.750Low
272.83KTurnover
LossP/E Static
-0.27P/B
0.00%Div Yield TTM
-211.28%ROA
34.27052wk High
0.91Volume Ratio
-72.81MNet Profit
7.03MShares
-40.5011EPS TTM
1.69Beta
--ROE
4.20052wk Low
9.14%Amplitude
24.08%Gross Margin
66.91MMarket Cap
0.71Reward/Risk
7.62%Risk Rate
TradingKey Stock Score of Scilex Holding Co
Currency: USD Updated: 2026-07-01Key Insights
Scilex Holding Co's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 119 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 490.00.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Scilex Holding Co's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Scilex Holding Co Highlights
StrengthsRisks
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 30.25M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 30.25M.
Overvalued
The company’s latest PE is -0.19, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 1.44M shares, increasing 21.79% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 41.07 shares of this stock.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
490.000
Target Price
+3319.40%
Upside Space
Scilex Holding Co News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Scilex Holding Co Info
Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.
Ticker SymbolSCLX
CompanyScilex Holding Co
CEOJi (Henry H)
Websitehttps://www.scilexholding.com/
Related Instruments
+0.11%
-0.37%
0.00%
0.00%
+0.80%
+0.94%
0.00%
+0.43%
0.00%
+0.38%
+0.59%
0.00%
+1.40%
0.00%
0.00%
0.00%
0.00%
+1.15%
0.00%
0.00%Popular Instruments
52370.200
+115.900 (+0.22%)
29882.900
+83.600 (+0.28%)
7493.600
+18.100 (+0.24%)
14801.000
-554.000 (-3.61%)
69109.000
-376.000 (-0.54%)
6342.200
+66.800 (+1.06%)
67.094
-0.874 (-1.29%)
295.250
+0.870 (+0.30%)
196.500
-1.080 (-0.55%)
4062.770
+32.000 (+0.79%)
FAQs
What is the current price of Scilex Holding Co (SCLX)?
The current price of Scilex Holding Co (SCLX) is 7.88.
What is the symbol of Scilex Holding Co?
The ticker symbol of Scilex Holding Co is SCLX.
What is the 52-week high of Scilex Holding Co?
The 52-week high of Scilex Holding Co is 34.27.
What is the 52-week low of Scilex Holding Co?
The 52-week low of Scilex Holding Co is 4.20.
What is the market capitalization of Scilex Holding Co?
The market capitalization of Scilex Holding Co is 66.91M.
Is Scilex Holding Co (SCLX) currently rated as Buy, Hold, or Sell?
According to analysts, Scilex Holding Co (SCLX) has an overall rating of signal_hold, with a price target of 490.00.
What is the Earnings Per Share (EPS TTM) of Scilex Holding Co (SCLX)?
The Earnings Per Share (EPS TTM) of Scilex Holding Co (SCLX) is -36.48.